160809-38-1

Basic information

• Product Name: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE
• Synonyms: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE;Ethyl 1-Cbz-piperidine-4-carboxylate;1,4-Piperidinedicarboxylic acid, 4-ethyl 1-(phenylMethyl) ester
• CAS NO: 160809-38-1
• Molecular Formula: C₁₆H₂₁NO₄
• Molecular Weight: 291.35
• Mol File: 160809-38-1.mol

Chemical Properties

• Boiling Point: 403.712°C at 760 mmHg
• Flash Point: 197.958°C
• Appearance: /
• Density: 1.166g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: 2-8°C
• PKA: -2.28±0.40(Predicted)
• CAS DataBase Reference: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE(160809-38-1)
• EPA Substance Registry System: 1-BENZYL 4-ETHYL PIPERIDINE-1,4-DICARBOXYLATE(160809-38-1)

Safety Data

• Hazardous Substances Data: 160809-38-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl 4-ethyl piperidine-1,4-dicarboxylate is used as a potential enzyme or receptor inhibitor for [application reason]. Its unique structural features and diverse biological activities make it a promising candidate for drug development in the pharmaceutical industry.

InChI:InChI=1/C16H21NO4/c1-2-20-15(18)14-8-10-17(11-9-14)16(19)21-12-13-6-4-3-5-7-13/h3-7,14H,2,8-12H2,1H3

Upstream product

• 1126-09-6 4-carbethoxypiperidine 
• 501-53-1 benzyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 75-03-6 ethyl iodide 

Downstream Products

• 160809-39-2 1-(benzyloxycarbonyl)-4-(1-hydroxy-1-methylethyl)piperidine 
• 173457-46-0 1-(Benzyloxycarbonyl)-4-(1-ethyl-1-hydroxypropyl)piperidine 
• 122860-33-7 benzyl 4-(hydroxymethyl)piperidine-N-carboxylate 
• 757239-38-6 4-[2-(tert-butyldimethylsilyloxy)-1-hydroxyethyl]-piperidine-1,4-dicarboxylic acid 1-benzyl ester 4-ethyl ester 
• 757239-40-0 4-hydroxy-2-oxa-8-aza-spiro[4.5]decane-8-carboxylic acid benzyl ester 
• 757239-39-7 4-(1,2-dihydroxyethyl)-1-hydroxymethyl-piperidine-1-carboxylic acid benzyl ester 
• 1013329-95-7 benzyl 4-(hydroxy(phenyl)methyl)piperidine-1-carboxylate 
• 922504-27-6 4-benzoylpiperidine-1-carboxylic acid benzyl ester 
• 916976-36-8 4-benzhydrylidene-piperidine-1-carboxylic acid benzyl ester 
• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 396073-62-4 4-((E)-5-Methoxycarbonyl-pent-1-enyl)-piperidine-1-carboxylic acid benzyl ester 
• 115-46-8 C₁₈H₂₁NO 
• 83799-24-0 fexofenadine 
• 105955-84-8 4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyraldehyde 

Relevant articles and documents

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).

CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

Caspase inhibitor and pharmaceutical composition, application and treatment method thereof

The invention provides a compound serving as a caspase inhibitor and particularly relates to a novel compound with caspase inhibition activity or a pharmaceutically acceptable salt of the novel compound, a preparation method of the novel compound and a ph

BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS.

This invention relates to compounds that are agonists of the muscarinic M1 receptor and/or M4 receptor and which are useful in the treatment of muscarinic M1/M4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds include those according to formula 1, or a salt thereof, wherein Q, R1 , R2, R3 and R4 are as defined herein.

Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL)

The key hydrolytic enzymes of the endocannabinoid system, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), are potential targets for various therapeutic applications. In this paper, we present more extensively the results of our previous work on piperazine and piperidine carboxamides and carbamates as FAAH and MAGL inhibitors. The best compounds of these series function as potent and selective MAGL/FAAH inhibitors or as dual FAAH/MAGL inhibitors at nanomolar concentrations. This study revealed that MAGL inhibitors should comprise leaving-groups with a conjugate acid pKa of 8-10, while diverse leaving groups are tolerated for FAAH inhibitors.

SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification.

AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment

AZOLE DERIVATIVES AS WTN PATHWAY INHIBITORS

The present invention relates to new compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy. Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway. For example, these may be used in preventing and/or retarding proliferation of tumor cells, for example carcinomas such as colon carcinomas.

Synthesis of diarylazepan-4-ones

Synthesis of several 3,3-diarylazepan-4-ones and 5,5-diarylazepan-4-ones has been established starting from two tetrasubstituted olefins, which is derived from commercially available piperidine-3-carboxylic acid ethyl ester and piperidine-4-carboxylic aci

1-PHENETHYLPIPERIDINE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS

This invention relates to novel 1-phenethylpiperidine derivatives of formuia (I) useful as opioid receptor ligands. More specifically, the invention provides compounds useful as μ opioid receptor ligands. In other aspects the invention relates to the use of these compounds in a method for therapy, such as for the treatment of pain, and to pharmaceutical compositions comprising the compounds of the invention.